Personalized mRNA Cancer Vaccines

Type: vaccine

Status: Breakthrough designation (FDA)

Developer: Moderna/BioNTech

Breakthrough Summary

No summary available.

Mechanism of Action

Custom mRNA encoding patient-specific neoantigens

Year: 2024-2026